Locations:

Tag: urothelial carcinoma

September 19, 2024/Cancer/Research

Identifying Pre-treatment Risk Factors of Developing Enfortumab Vedotin-Induced Peripheral Neuropathy in Patients with Locally Advanced/Metastatic Urothelial Carcinoma

Findings could help with management of a common, dose-limiting side effect

September 16, 2024/Cancer/Research

New Studies Reinforce Benefits of Combination Treatment for Urothelial Carcinoma

Enfortumab vedotin plus pembrolizumab benefited patients, regardless of biomarker expression

December 27, 2023/Cancer/Research

A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

November 19, 2019/Urology & Nephrology/Nephrology

Infiltrative Renal Masses: More Common Than Previously Thought and Often Unrecognized

Study examines how infiltrative features affect prognosis

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

BackPage 1 of 1Next